Literature DB >> 1484319

p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.

F G Mayall1, H Goddard, A R Gibbs.   

Abstract

The distinction between reactive mesothelium and mesothelioma in pleural biopsy specimens is notoriously difficult, and conventional immunohistochemical markers have provided no relief. The object of this study was to examine the frequency of immunohistochemically detectable p53 overexpression in routinely processed, paraffin-embedded tissue from pleural mesotheliomas and from pleura showing reactive mesothelial hyperplasia, using a polyclonal antibody to formalin-resistant p53 epitopes, and to consider the diagnostic utility of this antibody in the distinction between mesothelioma and reactive mesothelium in pleural biopsy specimens. Immunostaining was enhanced by pepsin predigestion prior to the application of the primary antibody. Positivity occurred in 10/16 epithelial mesotheliomas, 9/19 biphasic mesotheliomas, 2/12 sarcomatous mesotheliomas but in none of 20 reactive pleura. Immunostaining was particularly intense in some of the biopsy specimens, which may be due to the rapidity with which these small pieces of tissue were fixed. In conclusion, this study suggests that p53 immunostaining can help to distinguish epithelial or biphasic mesothelioma from reactive mesothelial hyperplasia in formalin-fixed, paraffin-embedded pleural biopsy specimens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1484319     DOI: 10.1002/path.1711680407

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  [Mesothelial proliferation in rectal cancer].

Authors:  P Adam; C Schraml; B Sipos; F Fend
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

2.  Malignant pericardial mesothelioma : A systematic review of current practice.

Authors:  S Cao; S Jin; J Cao; J Shen; H Zhang; Q Meng; B Pan; Y Yu
Journal:  Herz       Date:  2017-01-27       Impact factor: 1.443

Review 3.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

4.  Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.

Authors:  K Segers; H Backhovens; S K Singh; J De Voecht; M Ramael; C Van Broeckhoven; E Van Marck
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors.

Authors:  G Chemeris; A Loktinov; A Rempel; M Schwarz; P Bannasch
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

7.  Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.

Authors:  J Scurry; M A Duggan
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

8.  Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.

Authors:  L G Kindblom; M Ahldén; J M Meis-Kindblom; G Stenman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

Authors:  M Hsiao; J Low; E Dorn; D Ku; P Pattengale; J Yeargin; M Haas
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT.

Authors:  Ma Jinfeng; Wataru Kimura; Fumiaki Sakurai; Toshiyuki Moriya; Akiko Takeshita; Ichiro Hirai
Journal:  Int J Gastrointest Cancer       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.